{
  "first_published_at": "2013-11-15", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON336724", 
  "title": "Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery", 
  "tags": "{\"parsed_therapeutic\": [\"anaesthesia-intensive-care\", \"neurology\", \"ophthalmology\", \"psychiatry\"], \"Audience:\": [\"Secondary care\", \"Primary care\"], \"Therapeutic area:\": [\"Anaesthesia and intensive care\", \"Neurology\", \"Ophthalmology\", \"Psychiatry\"]}", 
  "_document_number": 47, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "anaesthesia-intensive-care", 
    "neurology", 
    "ophthalmology", 
    "psychiatry"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: November 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery have been reported in patients taking the atypical antipsychotics risperidone or paliperidone. IFIS may increase the risk of eye complications during and after cataract surgery<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Intraoperative floppy iris syndrome (IFIS) is a complication observed during cataract surgery that was first described in 2005 in association with the &#945;1-adrenergic antagonist tamsulosin.<cite>Chang DF, Campbell JR. J Cataract Refract Surg 2005; 31: 664&#8211;73.</cite> &#945;1-adrenergic receptors are present in the iris dilator muscle of the eye, where inhibition of the receptors relaxes this muscle causing a floppy iris and miosis.</p>\n\n<p>IFIS is characterised by a triad of intraoperative signs that may present with varying degrees of severity:</p>\n\n<ul>\n<li>billowing of a flaccid iris stroma</li>\n\n<li>progressive intraoperative pupil constriction</li>\n\n<li>propensity for iris prolapse towards the phaco and side port incisions</li>\n</ul>\n\n<p>Complications of IFIS during cataract surgery include: iris trauma; posterior capsule rupture; and vitreous loss. Postoperative complications include increased intraocular pressure and cystoid macular oedema.</p>\n\n<p>Cases of IFIS associated with the use of antipsychotic agents that have &#945;1-adrenergic receptor-blocking activity have been reported in the literature. Risperidone is an atypical antipsychotic with &#945;1-adrenergic antagonist actions. A review of postmarketing safety data identified six cases of IFIS during cataract surgery reported for risperidone worldwide. In two of these cases a causal relation between risperidone and IFIS is plausible. In both these cases, the patients had no history of taking other &#945;1-adrenergic antagonists. Both patients had received long-term treatment with risperidone and developed typical features of IFIS during cataract surgery. One patient continued treatment with risperidone and subsequently experienced a second episode of IFIS during cataract surgery on the second eye 4 months later.</p>\n\n<p>To date, no cases of IFIS have been reported for paliperidone; however, this drug is an active metabolite of risperidone and has &#945;1-adrenergic antagonist actions. Therefore, this information and advice applies also to paliperidone.</p>\n\n<p>Product information for <a href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm?subsName=RISPERIDONE&#38;pageID=SecondLevel\" target=\"_blank\">risperidone</a> and paliperidone has recently been updated to include warnings about IFIS.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Primary-care physicians should document the use of &#945;1-adrenergic antagonists&#8212;including risperidone and paliperidone&#8212;when making a referral for cataract surgery</li>\n\n<li>When taking a medication history before cataract surgery, patients should be questioned about current or past use of risperidone or paliperidone</li>\n\n<li>Cataract surgeons should approach surgery with caution in people with such a medication history. If IFIS is suspected, measures to prevent the iris from prolapsing during cataract surgery may be required</li>\n\n<li>The potential benefit of stopping risperidone or paliperidone before cataract surgery on the risk of IFIS has not been established and must be weighed against the risk of stopping antipsychotic therapy</li>\n\n<li>Please report suspected cases of IFIS occurring with &#945;1-adrenergic antagonists via the Yellow Card scheme (<a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>Letter for healthcare professionals <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON333631\" target=\"_blank\">sent Oct 17, 2013</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 4, November 2013: A6.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Intraoperative floppy iris syndrome (IFIS) is a complication observed during cataract surgery that was first described in 2005 in association with the &#945;1-adrenergic antagonist tamsulosin.<cite>Chang DF, Campbell JR. J Cataract Refract Surg 2005; 31: 664&#8211;73.</cite> &#945;1-adrenergic receptors are present in the iris dilator muscle of the eye, where inhibition of the receptors relaxes this muscle causing a floppy iris and miosis.</p>\n\n<p>IFIS is characterised by a triad of intraoperative signs that may present with varying degrees of severity:</p>\n\n<ul>\n<li>billowing of a flaccid iris stroma</li>\n\n<li>progressive intraoperative pupil constriction</li>\n\n<li>propensity for iris prolapse towards the phaco and side port incisions</li>\n</ul>\n\n<p>Complications of IFIS during cataract surgery include: iris trauma; posterior capsule rupture; and vitreous loss. Postoperative complications include increased intraocular pressure and cystoid macular oedema.</p>\n\n<p>Cases of IFIS associated with the use of antipsychotic agents that have &#945;1-adrenergic receptor-blocking activity have been reported in the literature. Risperidone is an atypical antipsychotic with &#945;1-adrenergic antagonist actions. A review of postmarketing safety data identified six cases of IFIS during cataract surgery reported for risperidone worldwide. In two of these cases a causal relation between risperidone and IFIS is plausible. In both these cases, the patients had no history of taking other &#945;1-adrenergic antagonists. Both patients had received long-term treatment with risperidone and developed typical features of IFIS during cataract surgery. One patient continued treatment with risperidone and subsequently experienced a second episode of IFIS during cataract surgery on the second eye 4 months later.</p>\n\n<p>To date, no cases of IFIS have been reported for paliperidone; however, this drug is an active metabolite of risperidone and has &#945;1-adrenergic antagonist actions. Therefore, this information and advice applies also to paliperidone.</p>\n\n<p>Product information for <a href=\"http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm?subsName=RISPERIDONE&amp;pageID=SecondLevel\" target=\"_blank\">risperidone</a> and paliperidone has recently been updated to include warnings about IFIS.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Primary-care physicians should document the use of &#945;1-adrenergic antagonists&#8212;including risperidone and paliperidone&#8212;when making a referral for cataract surgery</li>\n\n<li>When taking a medication history before cataract surgery, patients should be questioned about current or past use of risperidone or paliperidone</li>\n\n<li>Cataract surgeons should approach surgery with caution in people with such a medication history. If IFIS is suspected, measures to prevent the iris from prolapsing during cataract surgery may be required</li>\n\n<li>The potential benefit of stopping risperidone or paliperidone before cataract surgery on the risk of IFIS has not been established and must be weighed against the risk of stopping antipsychotic therapy</li>\n\n<li>Please report suspected cases of IFIS occurring with &#945;1-adrenergic antagonists via the Yellow Card scheme (<a href=\"http://www.mhra.gov.uk/yellowcard\" target=\"_blank\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p><strong>Further information</strong></p>\n\n<p>Letter for healthcare professionals <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON333631\" target=\"_blank\">sent Oct 17, 2013</a></p>\n\n<p><em>Article citation: Drug Safety Update volume 7 issue 4, November 2013: A6.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-11-01", 
  "date_last_modified": "2013-11-18", 
  "_assets": [], 
  "_item_id": 47, 
  "summary": "Cases of intraoperative floppy iris syndrome (IFIS) during cataract surgery have been reported in patients taking the atypical antipsychotics risperidone or paliperidone. IFIS may increase the risk of eye complications during and after cataract surgery", 
  "body": "Article date: November 2013\n\nIntraoperative floppy iris syndrome (IFIS) is a complication observed during cataract surgery that was first described in 2005 in association with the α1-adrenergic antagonist tamsulosin.[^1] α1-adrenergic receptors are present in the iris dilator muscle of the eye, where inhibition of the receptors relaxes this muscle causing a floppy iris and miosis. \n\nIFIS is characterised by a triad of intraoperative signs that may present with varying degrees of severity:  \n  \n  * billowing of a flaccid iris stroma  \n  * progressive intraoperative pupil constriction  \n  * propensity for iris prolapse towards the phaco and side port incisions  \n  \nComplications of IFIS during cataract surgery include: iris trauma; posterior capsule rupture; and vitreous loss. Postoperative complications include increased intraocular pressure and cystoid macular oedema.\n\nCases of IFIS associated with the use of antipsychotic agents that have α1-adrenergic receptor-blocking activity have been reported in the literature. Risperidone is an atypical antipsychotic with α1-adrenergic antagonist actions. A review of postmarketing safety data identified six cases of IFIS during cataract surgery reported for risperidone worldwide. In two of these cases a causal relation between risperidone and IFIS is plausible. In both these cases, the patients had no history of taking other α1-adrenergic antagonists. Both patients had received long-term treatment with risperidone and developed typical features of IFIS during cataract surgery. One patient continued treatment with risperidone and subsequently experienced a second episode of IFIS during cataract surgery on the second eye 4 months later.\n\nTo date, no cases of IFIS have been reported for paliperidone; however, this drug is an active metabolite of risperidone and has α1-adrenergic antagonist actions. Therefore, this information and advice applies also to paliperidone.\n\nProduct information for [risperidone](http://www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/index.htm?subsName=RISPERIDONE&pageID=SecondLevel) and paliperidone has recently been updated to include warnings about IFIS.\n\nAdvice for healthcare professionals:  \n  \n  * Primary-care physicians should document the use of α1-adrenergic antagonists—including risperidone and paliperidone—when making a referral for cataract surgery  \n  * When taking a medication history before cataract surgery, patients should be questioned about current or past use of risperidone or paliperidone  \n  * Cataract surgeons should approach surgery with caution in people with such a medication history. If IFIS is suspected, measures to prevent the iris from prolapsing during cataract surgery may be required  \n  * The potential benefit of stopping risperidone or paliperidone before cataract surgery on the risk of IFIS has not been established and must be weighed against the risk of stopping antipsychotic therapy  \n  * Please report suspected cases of IFIS occurring with α1-adrenergic antagonists via the Yellow Card scheme ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard))  \n  \nFurther information\n\nLetter for healthcare professionals [sent Oct 17, 2013](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON333631)\n\nArticle citation: Drug Safety Update volume 7 issue 4, November 2013: A6.\n\n[^1]: Chang DF, Campbell JR. J Cataract Refract Surg 2005; 31: 664–73.\n"
}